MedTrace Logo

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

NCT01838577 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2021-03-09

No results posted yet for this study

Summary

The investigators wish to document the distribution of EGFR somatic mutations, and assess the relationship between specific genotype, clinical demographic, therapy, and survival, in a large cohort of EGFR mutant NSCLC.

The investigators also wish to comprehensively investigate the relationship between germline DNA and risk of EGFR mutant NSCLC developing, through a GWAS (Genome-Wide Association Studies) and candidate gene approach, and explore the relationship between germline DNA and clinical outcome, in order to potentially identify germline genetic modifiers of EGFR TKI (Tyrosine Kinase Inhibitor) outcome.

Conditions

  • EGFR Mutation Positive Non Small Cell Lung Cancer

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Sanjay Popat, MD · Royal Marsden Hospital, Chelsea, London, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2021-12-31
Completion
2022-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838577 on ClinicalTrials.gov